Philips, the lighting company best known for their interior lighting solutions, has just launched a pioneering new wearable treatment for psoriasis that utilizes blue LED lights. Psoriasis is a skin disease that affects some 125 million people worldwide, causing inflammation, scaly red patches and peeling of the skin. Philip’s clinical trials have shown that their BlueControl treatment can reduce the severity of outbreaks without the risk of side effects associated with other clinical treatments.
The most common form of psoriasis—psoriasis vulgaris—is chronic and incurable. Treatments to reduce the symptoms include topical applications, prescription drugs and UV phototheraphy—a treatment which often requires frequent visits to doctors’ offices. The BlueControl device works differently than any current modes of treatment: 40 non-UV blue LED lights are strapped to a fabric strap that can be placed around affected areas of the legs, arms, elbows and knees.
The LEDs are different from those used in conventional applications; as Philips explains, the lights feature “high intensities and tailored adjustments such as pulsed LED light.” The battery-powered device can be worn “anytime and anywhere,” and Philips claims that the treatment reduces the amount of time spent visiting with physicians. Moreover, based on the clinical trials conducted by the manufacturer, in partnership with the University Hospital of Aachen, the BlueControl treatment “showed a 50% reduction on average of symptoms according to the Local Psoriasis Area Severity Index (PASI) which measures the severity of psoriasis plaques (thickness, redness and scaling). No negative side-effects of the blue LED light treatment were observed.”
BlueControl will be available by prescription in the UK, the Netherlands and Germany starting this month.